Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
A nanoparticle, non-nanoparticle technology for the treatment of acute and chronic pain and inflammation that addresses acute pain and inflammation in undescribed topical formulations
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
example 1
[0027]LiNTEC nanosizing technology: solid particles of active pharmaceutical ingredients (such as NSAIDs and / or local anesthetics as described above) are dispersed in an aqueous solvent (such as water), vortexed and / or sonicated, with some particles going into solution , and some particles remain in solid form. Subsequently, solutions and suspensions of the active pharmaceutical ingredient are subjected to LiNTEC nanosizing technology by laser irradiation with irradiation of an appropriate wavelength according to the specific pharmaceutical agent used. The resulting formulations are solutions and nanoparticle suspensions of the active pharmaceutical ingredient, wherein the nanoparticle size ranges from 5 to 500 nm, preferably from 10 to 200 nm and most preferably from 20 to 100 nm. This formulation is then used in pharmaceutical formulations suitable for topical and / or transdermal delivery.
example 2
[0028] Example 2 (patch containing only piroxicam)
[0029] A transdermal patch was prepared for the treatment of acute and chronic pain and inflammation in humans with an adhesive material containing 60 mg of piroxicam nanoparticle suspension / solution prepared according to the procedure described in Example 1 in an aqueous base. It will be applied by the patient once a day, every 2 days, every 3 days, or every 5 to 7 days to the skin in areas that feel pain (eg, knees, shoulders, lower back). The patch may have 30 mg, 40 mg, 50 mg, 70 mg, 80 mg or 100 mg of piroxicam instead of 60 mg of piroxicam. The size of the patch can be 2cm×3cm, 3cm×4cm, 5cm×7cm, 7cm×10cm, 10cm×14cm, etc.
example 3
[0030] Example 3 (patch containing piroxicam and lidocaine)
[0031] Preparation of a transdermal patch for the treatment of acute and chronic pain and inflammation in humans with an adhesive adhesive containing 60 mg of piroxicam nanoparticle suspension / solution prepared according to the technique described in Example 1 and 900 mg of lidocaine in an aqueous base Material. It will be applied by the patient once a day, every 2 days, every 3 days, or every 5 to 7 days to the skin in areas that feel pain (eg, knees, shoulders, lower back). The patch may have any pharmaceutically suitable combination of 30mg, 40mg, 50mg, 70mg, 80mg or 100mg of piroxicam and 200mg, 300mg, 400mg, 500mg, 600mg, 700mg, 800mg, 1,000mg, 1,500mg or 2,000mg of lidocaine , instead of having 60mg piroxicam and 900mg lidocaine. The size of the patch can be 3cm×5cm, 5cm×7cm, 7cm×10cm, 10cm×14cm, etc.
PUM
Property | Measurement | Unit |
---|---|---|
size | aaaaa | aaaaa |
size | aaaaa | aaaaa |
size | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com